Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase IIa trials of PT-141 in FSD and ED complete enrollment

Jan. 18, 2005

Phase III study of ferumoxytol as intravenous iron replacement therapy

Jan. 18, 2005

Yasmin receives Canadian approval

Jan. 17, 2005

Two clinical studies support the use of recombinant human albumin as an alternative to HSA

Jan. 14, 2005

Amgen's thrombopoietin receptor ligand AMG-531 tested in healthy individuals

Jan. 13, 2005

Novel peptide enhances the effects of BMP-2 in vitro

Jan. 13, 2005

Kalypsys patent covers novel PPAR modulators for obesity, diabetes, etc.

Jan. 12, 2005

Thiazolidinedione derivatives claimed by Incyte

Jan. 12, 2005

Treatment phase begins in SHEPHERD study of eculizumab for PNH

Jan. 12, 2005

Sangamo submits IND for SB-509 to treat diabetic neuropathy

Jan. 12, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...